Role of nitric oxide in pathogenesis of tumor growth and its possible application in cancer treatment
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13515Keywords:
antitumor therapy, malignant tumors, nitric oxide, radiosensitizationAbstract
Summary. In this review, the role of nitric oxide (NO) in the pathogenesis of the tumor growth and possibilities of its application in the treatment of cancer patients are analyzed. NO is one of the most important mediators of physiological processes being involved in the regulation of practically all body functions in health and disease. The role of NO in the development of many pathological conditions has been extensively studied and debated in recent years. Today it is clear that NO in relation to malignant tumors may exhibit a dual activity — can stimulate tumor growth and cause an opposite antitumor effect. Effects of NO are mostly dependent on its concentration. At low concentrations, NO could inhibit apoptosis and cause mutations that potentially lead to the formation of malignant growth loci. However, a high concentration of NO appears to be detrimental to malignant cells, in particular under conditions of simultaneous exposure to ionizing radiation. In humans, the inducible NO synthase (iNOS, type II) is the most powerful form of NO synthases (NOS) and has the ability to synthesize large amounts of NO for a long time and exert a protective function. iNOS is expressed in macrophages, monocytes, neutrophils, fibroblasts, hepatocytes, and other cell types. In tissue of malignant tumors, the macrophagal iNOS is the main form. Experimental data provide an evidence that activated macrophages and leukocytes, which are the part of peritumorous inflammatory infiltrate, can provide radiosensitization of tumors by direct synthesis of NO and indirectly — through the secretion of cytokines stimulating iNOS activity in cancer cells. Such approach could be useful for the development of new schemes and methods of anticancer therapy based on the activation of endogenous NO biosynthesis pathways.
References
Blaise GA, Gauvin D, Gangal M, et al. Nitric oxide, cell signaling and cell death. Toxicology 2005; 208: 177–92.
Mashyna SJu, Vanin AF, Serezhenkov VA. Identification and evaluation of NO depot in the body of the conscious rat. Bull Exp Biol 2003; 316: 32–6 (in Russian).
Burlaka AP, Sidorik EP. Redox-dependent signal molecules in the mechanisms of tumor process. Naukova Dumka, 2014. 255 p. (in Russian).
Bonavida B. Nitric oxide and cancer: pathogenesis and therapy. Springer, 2015. 308 p.
Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics. Int J Oncol 2008; 33: 909–27.
Cheng H, Wang L, Mollica M, et al. Nitric oxide in cancer metastasis. Cancer Lett 2014; 353: 1–7.
Donia M, Maksimovic-Ivanic D, Mijatovic S, et al. In vitro and in vivo anticancer action of saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 2011; 10: 492–9.
Golotiuk VV. Peculiarities of the distribution and dynamics of Bax apoptotic marker expression in patients with rectal cancer under the influence of neoadjuvant chemoradiotherapy with the use of nitrogen oxide precursor. Patologija 2015; 2: 71–4 (in Ukrainian).
Golotiuk VV, Bagrij MM. Features of the distribution and dynamics of inducible nitric oxide synthase expression in patients with rectal cancer under the influence of neoadjuvant chemoradiation therapy and their relationship to the effectiveness of radiomodification with the use L-arginine. Morfologija 2016; 10: 99–103 (in Ukrainian).
Mojic M, Mijatovic S, Maksimovic-Ivanic D, et al. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Mol Pharmacol 2012; 82: 700–10.
Aranda E, Lopez-Pedrera C, De La Haba-Rodriguez JR, et al. Nitric oxide and cancer: the emerging role of S nitrosylation. Curr Mol Med 2012; 12: 50–67.
Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009; 15: 391–404.
Hess DT, Stamler JS. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem 2011; 287: 4411–8.
Osborne NN. A hypothesis to suggest that light is a risk factor in glaucoma and mitochondrial optic neuropathies. Br J Ophthalmol 2006; 2: 237–41.
Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277–89.
Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res 2013; 19: 5557–63.
Wink DA, Hines HB, Cheng RY, et al. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011; 89: 873–91.
Choudhari SK, Chaudhary M, Bagde S, et al. Nitric oxide and cancer: a review. World J Surg Oncol 2013; 11: 18–27.
Malakhov VO, Zavgorodnyaya GM, Licko VS, et al. The problem of nitric oxide in neurology. Sumy State Pedagogical University by A.S. Makarenko, 2009. 241 p. (in Russian).
Brown GC. Nitric oxide and mitochondria. Front Biosci 2007; 12: 1024–33.
Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 2524–31.
Giulivi C. Mitochondria as generators and targets of nitric oxide. Novartis Found Symp 2007; 287: 92–104.
Lacza Z, Pankotai E, Csordás A, et al. Mitochondrial NO and reactive nitrogen species production: does mtNOS exist? Nitric Oxide 2006; 14: 162–8.
Weigert A, Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 2008; 19: 95–102.
Burlaka AP, Vovk AV, Burlaka AA, et al. Rectal cancer: redox state of venous blood and tissues of blood vessels from electron paramagnetic resonance and its correlation with the five-year survival. Biomed Res Int 2018; 2018: 4848652.
Domina EA, Mikhailenko VM, Pylypchuk EP. Influence of nitrogen oxide on formation of chromosomic instability in lymphocytes of blood human in conditions of co-mutagen modification. Science Rise 2015; 2/1: 7–10 (in Ukrainian).
Mikhailenko VM, Diomina EA, Muzalov II, et al. Nitric oxide coordinates development of genomic instability in realization of combined effect with ionizing radiation. Exp Oncol 2013; 35: 58–64.
Rahat MA, Hemmerlein B. Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol 2013; 4: 144–5.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436–44.
Moeller BJ, Dewhirst MW. HIF-1 and tumour radiosensitivity. Br J Cancer 2006; 95: 1–5.
Shinojima T, Oya M, Takayanagi A, et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis 2007; 28: 529–36.
Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: Novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008; 19: 205–16.
Chowdhury R, Godoy LC, Thiantanawat A, et al. Nitric oxide produced endogenously is responsible for hypoxia-induced HIF-1alpha stabilization in colon carcinoma cells. Chem Res Toxicol 2012; 25: 2194–202.
Fitzpatrick B, Mehibel M, Cowen RL, et al. INOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217–24.
Jeannin JF, Leon L, Cortier M, et al. Nitric oxide-induced resistance or sensitization to death in tumor cells. Nitric Oxide 2008; 19: 158–63.
Leon L, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide 2008; 19: 77–83.
Burlaka AP, Vovk AV, Ganusevych II, et al. Superoxide- and NO-dependent mechanisms of formation of metastatic microenvironment distant sites of metastasis in patients with colorectal cancer. Oncology 2017; 19: 64–70 (in Ukrainian).
Singh S, Gupta AK. Mini review nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 2011; 67: 1211–24.
De Ridder M, Verovski VN, Darville MI. Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse. Int J Radiat Oncol Biol Phys 2004; 60: 598–606.
Lee DH, Pfeifer GP. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis 2007; 22: 63–7.
Cook T, Wang Z, Alber S. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 2004; 64: 8015–21.
Schneiderhan N, Budde A, Zhang Y, et al. Nitric oxide induces phosphorylation of p53 and impairs nuclear export. Oncogene 2003; 22: 2857–68.
Chung P, Cook T, Liu K, et al. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide 2003; 8: 119–26.
Jordan BF, Misson PD, Demeure R, et al. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48: 565–70.
Yanish YuV, Artamonova AB, Zaletok SP. Impact of arginine and polyamines metabolism modulators on the arginaze activity and nitrogen oxides production by cells of Ehrlich carcinoma in vivo. Clin Oncol 2016; 2: 1–3 (in Ukrainian).
Gochman E, Mahajna J, Shenzer P, et al. The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem 2012; 114: 827–35.
Ropponen KM, Kellokoski JK, Lipponen PK, et al. Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol 2000; 11: 1204–11.
Cianchi F, Cortesini C, Fantappie O, et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am J Pathol 2003; 162: 793–801.
Moochhala S, Chhatwal VJ, Chan ST, et al. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996; 17: 1171–4.
Ambs S, Bennett WP, Merriam WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999; 9: 86–8.
Ohta T, Takahashi M, Ochiai A. Increased protein expression of both inducible nitricoxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett 2006; 239: 246–53.
Zafirellis K, Zachaki A, Agrogiannis G, et al. Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer. APMIS 2010; 118: 115–24.
Lagares-Garcia JA, Moore RA, Collier B, et al. Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 2001; 67: 709–13.
Nozoe T, Yasuda M, Honda M, et al. Immunohistochemical expression of cytokine induced nitric oxide synthase in colorectal carcinoma. Oncol Rep 2002; 9: 521–4.
Yu Qin. The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncol 2005; 1: 475–84.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
